Physician

Daniel Jae Kim, M.D.

According to 2025 Medicare claims, Daniel Kim, M.D. (NPI: 1033291562) practices hematology/oncology in the Los Angeles-Long Beach-Glendale, CA market, with the plurality of this provider's patient population coming from Los Angeles, CA. This provider's primary affiliated billing organization is CITY OF HOPE MEDICAL FOUNDATION (NPI: 1871886366; TIN: 274803222) and primary practice location at 91030-1814.

Kim's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 708 traditional Medicare patients, billed 243,953 HCPCS/CPT codes, and received $4,480,781 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,257 prescription claims across 203 beneficiaries totaling $4,596,558 in drug costs, led by Tagrisso (Osimertinib Mesylate). DME data shows 28 claims. Open Payments data shows 1 records totaling $22. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $61,932 to $4,480,781. Similarly, Part D prescription costs have risen steadily, from $524,874 to $4,596,558. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	113	957	$61,932
2016	98	529	$54,524
2017	127	585	$50,835
2018	298	48,336	$722,825
2019	307	83,540	$1,476,398
2020	326	103,993	$1,775,468
2021	478	132,710	$2,490,152
2022	539	194,965	$3,899,800
2023	629	225,866	$4,001,100
2024	708	243,953	$4,480,781

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	97	395	$524,874
2016	61	344	$798,456
2017	72	461	$1,638,524
2018	200	785	$1,260,002
2019	237	1,243	$2,492,940
2020	191	1,065	$2,542,932
2021	176	868	$2,402,027
2022	172	985	$2,740,697
2023	182	1,039	$3,639,270
2024	203	1,257	$4,596,558

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	16	$21,602
2016	N/R	67	$34,965
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	14	$2,546
2021	N/R	98	$29,743
2022	N/R	113	$14,587
2023	N/R	78	$15,842
2024	N/R	28	$1,117

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	176	668	$159
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	194	225	$145
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	337	784	$108
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	191	1,132	$99
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	279	658	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	71	2,130	$1,154,323
Revlimid	Lenalidomide	31	868	$556,826
Imbruvica	Ibrutinib	32	896	$505,477
Ibrance	Palbociclib	22	616	$341,242
Abiraterone Acetate	Abiraterone Acetate	74	2,205	$221,605

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$872
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$245

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$22	Janssen Pharmaceuticals, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daniel Jae Kim, M.D.?

Tedicare shows public-source Medicare data for Daniel Jae Kim, M.D. (NPI 1033291562), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel Jae Kim, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Daniel Jae Kim, M.D.?

Daniel Jae Kim, M.D. is linked to CITY OF HOPE MEDICAL FOUNDATION (billing NPI 1871886366) in the available physician profile data.

Does Daniel Jae Kim, M.D. have Open Payments data?

Daniel Jae Kim, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.